piperaquine has been researched along with lumefantrine in 50 studies
| Studies (piperaquine) | Trials (piperaquine) | Recent Studies (post-2010) (piperaquine) | Studies (lumefantrine) | Trials (lumefantrine) | Recent Studies (post-2010) (lumefantrine) |
|---|---|---|---|---|---|
| 638 | 227 | 497 | 487 | 123 | 298 |
| Protein | Taxonomy | piperaquine (IC50) | lumefantrine (IC50) |
|---|---|---|---|
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 5.5351 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (22.00) | 29.6817 |
| 2010's | 33 (66.00) | 24.3611 |
| 2020's | 6 (12.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anstey, NM; Brockman, A; Chalfein, F; Cheng, Q; Kenangalem, E; Piera, K; Prasetyorini, B; Prayoga, P; Price, RN; Russell, B; Sugiarto, P; Suwanarusk, R; Tjitra, E | 1 |
| Anstey, NM; Chalfien, F; Hasugian, AR; Kenangalem, E; Marfurt, J; Penttinen, PM; Piera, KA; Price, RN; Purba, HL; Ratcliff, A; Russell, B; Siswantoro, H; Tjitra, E; Wuwung, RM | 1 |
| Masseno, V; Muriithi, S; Nzila, A | 1 |
| Abdirahman, A; Borrmann, S; Bull, P; Diriye, A; Kiara, SM; Marsh, K; Mwai, L; Nzila, A; Pole, L; Rippert, A | 1 |
| Greenhouse, B; Joloba, M; Kiggundu, M; Nanyunja, S; Nsobya, SL; Rosenthal, PJ | 1 |
| Borrmann, S; Kiara, SM; Mwai, L; Nzila, A; Ochola, LI; Ohuma, E; Okombo, J; Pole, L; Rono, J | 1 |
| Biamonte, MA; Le Roch, KG; Wanner, J | 1 |
| Bane, CE; Black, C; Butler, K; Caridha, D; Cooper, RA; Dodean, RA; Gaona, H; Gaynor-Ohnstad, L; Huezo, SJ; Kancharla, P; Kelly, JX; Kreishman-Deitrick, M; Leed, SE; Li, Q; Li, Y; Lin, H; Luong, TL; Marcsisin, S; Melendez, V; Nolan, C; Olmeda, R; Potter, B; Pou, S; Rasmussen, SA; Read, L; Riscoe, MK; Roncal, N; Sciotti, RJ; Smilkstein, MJ; Sousa, J; Stephens, MT; Tan, JC; Vesely, B; Vuong, C; Winter, RW; Xie, L; Zeng, Q; Zhang, J; Zhang, P | 1 |
| Cheong, SL; Ng, CH; Tibon, NS | 1 |
| Bane, CE; Bayles, BR; Black, C; Butler, K; Caridha, D; Ceja, FG; Cooper, RA; Dodean, RA; Gaona, H; Gaynor-Ohnstad, L; Kancharla, P; Kelly, JX; Kreishman-Deitrick, M; Leed, SE; Li, Q; Li, Y; Lin, H; Luong, TL; Marcsisin, S; Melendez, V; Mu, J; Nolan, C; Olmeda, R; Potter, B; Pou, S; Pybus, B; Rasmussen, SA; Read, L; Reynolds, KA; Riscoe, MK; Roncal, N; Rosenthal, PJ; Sciotti, RJ; Smilkstein, MJ; Sousa, J; Tumwebaze, PK; Vesely, B; Vuong, C; Xie, L; Zeng, Q; Zhang, J; Zhang, P | 1 |
| Bukirwa, H; Dorsey, G; Kamya, MR; Lugemwa, M; Rosenthal, PJ; Rwakimari, JB; Staedke, SG; Talisuna, A; Wabwire-Mangen, F; Yeka, A | 1 |
| Christophel, E; Hu, XM; Lin, SG; Liu, J; Meng, F; Wang, GZ; Wang, SQ; Zeng, LH | 1 |
| Davis, TM; Gomorrai, PS; Griffin, S; Ilett, KF; Karunajeewa, HA; Kotab, K; Lautu, D; Law, I; Lin, E; Mueller, I; Oa, O; Page-Sharp, M; Salman, S; Senn, M; Siba, P; Suano, P; Tarongka, N; Ura, A; Wong, R | 1 |
| Dorsey, G; Nosten, F; Price, RN | 1 |
| Abiodun, O; Bell, A; Brun, R; Chollet, J; Irungu, BN; Kiboi, DM; Langat, B; Nganga, JK; Nyambati, VC; Nzila, A; Rukunga, GM; Wittlin, S | 1 |
| Donegan, S; Garner, P; Olliaro, P; Sinclair, D; Zani, B | 1 |
| Bacchieri, A; Bassat, Q; Borrmann, S; Corsi, M; D'Alessandro, U; Menéndez, C; Mulenga, M; Nabasumba, C; Nambozi, M; Piola, P; Sasi, P; Talisuna, A; Tinto, H; Ubben, D; Valéa, I | 1 |
| Dokomajilar, C; Greenhouse, B; Ouédraogo, JB; Rosenthal, PJ; Rouamba, N; Séré, YY; Somé, AF; Zongo, I | 1 |
| Adam, I; Elhassan, AH; Elmardi, KA; Eltahir, HG; Malik, EM; Salah, MT | 1 |
| Arinaitwe, E; Bigira, V; Creek, D; Dorsey, G; Kakuru, A; Kamya, MR; Sandison, TG; Tappero, J; Wanzira, H | 1 |
| Faye, B; Faye, O; Kane, D; Kassi, KF; Kiki Barro, CP; Kone, M; Kuete, T; Menan, H; N'diaye, JL; Oga, AS; Same-Ekobo, A; Tine, R; Vicky, AM; Yavo, W | 1 |
| Adjalley, SH; Eappen, AG; Eastman, RT; Ekland, EH; Fidock, DA; Hoffman, SL; Johnston, GL; Lee, MC; Li, T; Richman, A; Sim, BK | 1 |
| Achan, J; D'Alessandro, U; Talisuna, AO; Tibenderana, J; Yeka, A | 1 |
| Arzika, I; Fandeur, T; Guillebaud, J; Issaka, M; Maazou, A; Salissou, A; Specht, S; Zamanka, H | 1 |
| Burkholder, B; Bustos, MD; Delacollette, C; Wongsrichanalai, C | 1 |
| Amalvict, R; Baret, E; Dormoi, J; Pradines, B; Savini, H | 1 |
| Baker, M; Bousema, T; Cairns, M; D'Alessandro, U; Ferguson, NM; Ghani, AC; Griffin, JT; Hugo, P; Jagoe, G; Okell, LC; Tarning, J; Ubben, D | 1 |
| Irungu, B; Kamau, L; Kiboi, D; Ngángá, J; Nzila, A; Ochola-Oyier, LI; Orwa, J | 1 |
| Burugu, MW; Gimode, WR; Kiboi, DM; Kimani, FT; Muregi, FW; Wamakima, HN | 1 |
| Bigira, V; Bloome, J; Byaruhanga, O; Conrad, MD; Cooper, RA; Dorsey, G; Greenhouse, B; Gut, J; Havlir, DV; Kakuru, A; Kamya, MR; Kapisi, J; Kozak, B; LeClair, N; Legac, J; Nakazibwe, C; Nsobya, SL; Okiring, J; Rosenthal, PJ; Tumwebaze, P; Walakira, A | 1 |
| Cabrera, M; Cui, L | 1 |
| Acheampong, PR; Antwi, GD; Bart Plange, C; Cairns, M; Chandramohan, D; Tagbor, H | 1 |
| Raju, KS; Singh, SP; Taneja, I; Wahajuddin, M | 1 |
| Anvikar, AR; Arora, S; Bose, TK; Enosse, S; Gaye, O; Iyer, SS; Jalali, RK; Jha, AC; Kokolomami, J; Krudsood, S; Mohanty, R; Mohanty, S; Mwapasa, V; Ndiaye, JL; Noedl, H; Nyirenda, M; Rao, BHK; Rao, BS; Rao, D; Roy, A; Sagara, I; Saha, N; Sharma, P; Sidibe, B; Starzengruber, P; Swoboda, P; Tangpukdee, N; Thompson, R; Tiacoh, L; Toure, OA; Tshefu, AK; Valecha, N; Yumva, NN | 1 |
| Amalvict, R; Benoit, N; Diatta, B; Diawara, S; Diémé, Y; Fall, B; Fall, M; Gendrot, M; Madamet, M; Nakoulima, A; Pradines, B; Wade, B; Wade, KA | 1 |
| Bélard, S; Damm, G; Kim, J; Kurth, F; Lingscheid, T; Mayer, B; Menner, N; Pongratz, P; Salama, A; Seehofer, D; Stegemann, MS; Steiner, F; Suttorp, N; von Bernuth, H; Zoller, T | 1 |
| Kofoed, PE; Rodrigues, A; Rombo, L; Ursing, J | 1 |
| Bouhired, S; Duparc, S; Goyal, N; Green, JA; Hussaini, A; Jones, SW; Koh, GC; Kostov, I; Mohamed, K; Taylor, M; Wolstenholm, A | 1 |
| Amalvict, R; Benoit, N; Briolant, S; Diatta, B; Diawara, S; Diémé, Y; Fall, B; Fall, M; Gendrot, M; Kounta, MB; Madamet, M; Nakoulima, A; Pradines, B; Wade, B; Wade, KA | 1 |
| Nosten, F | 1 |
| Byaruhanga, O; Ceja, FG; Conrad, MD; Cooper, RA; Katairo, T; Nsobya, SL; Rasmussen, SA; Rosenthal, PJ; Tumwebaze, PK | 1 |
| Adewoye, EO; Agomo, C; Akano, K; Ambe, J; Ayede, AI; Ebenebe, J; Emechebe, G; Ezeigwe, N; Fatunmbi, B; Finomo, F; Folarin, OA; Gbotosho, GO; Happi, CT; Jiya, N; Mokuolu, O; Ntadom, G; Oguche, S; Oyibo, WA; Sowunmi, A; Useh, F; Wammanda, R; Wewe, OA | 1 |
| Dama, S; de Smet, M; Djimdé, A; Doumbo, OK; Etard, JF; Grandesso, F; Guindo, O; Laminou, IM; Makarimi, R; Ouwe Missi Oukem-Boyer, O; Rigal, J; Traore, A; Woi Messe, L | 1 |
| Agarwal, P; Anvikar, AR; Pillai, CR; Srivastava, K | 1 |
| Asua, V; Conrad, MD; Dorsey, G; Kamya, MR; Kigozi, SP; Legac, J; Nsobya, SL; Rosenthal, PJ; Vinden, J | 1 |
| Chy, S; Felger, I; Hastings, I; Hodel, EM; Jones, S; Kay, K; Mbituyumuremyi, A; Menard, D; Uwimana, A | 1 |
| Bah, S; Dabitao, D; Dama, S; Diakité, M; Diakité, SAS; Doumbia, S; Doumbouya, M; Guindo, MA; Keita, B; Konaté, DS; Sangaré, M; Sanogo, I; Traoré, K | 1 |
| Abuaku, B; Duah-Quashie, NO; Hagan, CO; Hodoameda, P; Koram, K; Matrevi, S; Quashie, NB | 1 |
| Conrad, MD; Cooper, RA; Duvalsaint, M; Legac, J; Rosenthal, PJ; Tukwasibwe, S; Tumwebaze, PK | 1 |
| Chepngetich, J; Gachie, B; Gathirwa, J; Kiboi, D; Kimani, F; Magoma, G; Muriithi, B; Mwitari, P; Onchieku, N; Thiong'o, K | 1 |
4 review(s) available for piperaquine and lumefantrine
| Article | Year |
|---|---|
Recent advances in malaria drug discovery.
Topics: Animals; Antimalarials; Drug Discovery; Humans; Liver; Liver Transplantation; Malaria; Molecular Structure | 2013 |
Current progress in antimalarial pharmacotherapy and multi-target drug discovery.
Topics: Animals; Antimalarials; Artemisinins; Drug Discovery; Drug Resistance; Humans; Malaria; Molecular Structure; Paclitaxel; Quinolines | 2020 |
Artemisinin-based combination therapy for treating uncomplicated malaria.
Topics: Antimalarials; Artemisinins; Artesunate; Drug Combinations; Drug Therapy, Combination; Ethanolamines; Fluorenes; Humans; Lumefantrine; Malaria; Malaria, Falciparum; Malaria, Vivax; Mefloquine; Parasitemia; Pyrimethamine; Quinolines; Randomized Controlled Trials as Topic; Sulfadoxine | 2009 |
Monitoring antimalarial drug efficacy in the Greater Mekong Subregion: an overview of in vivo results from 2008 to 2010.
Topics: Antimalarials; Artemether; Artemisinins; Artesunate; Asia, Southeastern; Chloroquine; Directly Observed Therapy; Drug Resistance; Drug Therapy, Combination; Ethanolamines; Fluorenes; Humans; Lumefantrine; Malaria, Falciparum; Malaria, Vivax; Mefloquine; Parasitemia; Quinolines | 2013 |
15 trial(s) available for piperaquine and lumefantrine
| Article | Year |
|---|---|
In vitro sensitivities of Plasmodium falciparum to different antimalarial drugs in Uganda.
Topics: Antimalarials; Child; Child, Preschool; Cohort Studies; Drug Resistance; Humans; Malaria, Falciparum; Membrane Transport Proteins; Multidrug Resistance-Associated Proteins; Parasitic Sensitivity Tests; Plasmodium falciparum; Polymorphism, Genetic; Protozoan Proteins; Treatment Outcome; Uganda | 2010 |
Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda.
Topics: Antimalarials; Artemether; Artemisinins; Child; Child, Preschool; Drug Therapy, Combination; Ethanolamines; Fluorenes; Health Policy; Humans; Infant; Lumefantrine; Malaria, Falciparum; Quinolines; Uganda | 2008 |
[Efficacy of dihydroartemisinin-piperaquine and artemether-lumefantrine in the treatment of uncomplicated falciparum malaria in Hainan, China].
Topics: Adolescent; Adult; Aged; Animals; Antimalarials; Artemether; Artemisinins; Child; Child, Preschool; China; Dose-Response Relationship, Drug; Drug Combinations; Ethanolamines; Female; Fluorenes; Follow-Up Studies; Humans; Infant; Lumefantrine; Malaria, Falciparum; Male; Middle Aged; Quinolines; Treatment Outcome; Young Adult | 2008 |
A trial of combination antimalarial therapies in children from Papua New Guinea.
Topics: Antimalarials; Artemether; Artemisinins; Artesunate; Child, Preschool; Chloroquine; Drug Therapy, Combination; Ethanolamines; Female; Fluorenes; Humans; Infant; Kaplan-Meier Estimate; Lumefantrine; Malaria, Falciparum; Malaria, Vivax; Male; Proportional Hazards Models; Pyrimethamine; Quinolines; Recurrence; Sulfadoxine | 2008 |
Dihydroartemisinin-piperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children: a randomised, non-inferiority trial.
Topics: Africa; Antiparasitic Agents; Artemether; Artemisinins; Child, Preschool; Drug Therapy, Combination; Ethanolamines; Fluorenes; Humans; Infant; Lumefantrine; Malaria; Malaria, Falciparum; Plasmodium falciparum; Polymerase Chain Reaction; Quinolines; Time Factors | 2009 |
Dihydroartemisinin-piperaquine versus artemether-lumefantrine, in the treatment of uncomplicated Plasmodium falciparum malaria in central Sudan.
Topics: Antimalarials; Artemisinins; Child; Child, Preschool; Drug Therapy, Combination; Ethanolamines; Fluorenes; Humans; Lumefantrine; Malaria, Falciparum; Plasmodium falciparum; Quinolines; Sudan; Treatment Outcome | 2010 |
Increased risk of early vomiting among infants and young children treated with dihydroartemisinin-piperaquine compared with artemether-lumefantrine for uncomplicated malaria.
Topics: Antimalarials; Artemether; Artemisinins; Child, Preschool; Ethanolamines; Fluorenes; Humans; Infant; Lumefantrine; Malaria; Quinolines; Risk; Uganda; Vomiting | 2010 |
Comparative study of the efficacy and tolerability of dihydroartemisinin-piperaquine-trimethoprim versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Cameroon, Ivory Coast and Senegal.
Topics: Adolescent; Adult; Animals; Antimalarials; Artemether; Artemisinins; Cameroon; Child; Child, Preschool; Cote d'Ivoire; Drug Therapy, Combination; Ethanolamines; Female; Fluorenes; Humans; Lumefantrine; Malaria, Falciparum; Male; Middle Aged; Quinolines; Senegal; Treatment Outcome; Trimethoprim; Young Adult | 2011 |
Efficacy of quinine, artemether-lumefantrine and dihydroartemisinin-piperaquine as rescue treatment for uncomplicated malaria in Ugandan children.
Topics: Antimalarials; Artemether; Artemisinins; Child, Preschool; Ethanolamines; Fluorenes; Humans; Infant; Lumefantrine; Malaria, Falciparum; Male; Quinine; Quinolines; Safety; Treatment Outcome; Uganda | 2013 |
Seasonal malaria chemoprevention in an area of extended seasonal transmission in Ashanti, Ghana: an individually randomised clinical trial.
Topics: Amodiaquine; Antimalarials; Artemether; Artemisinins; Chemoprevention; Child, Preschool; Drug Combinations; Drug Therapy, Combination; Ethanolamines; Female; Fluorenes; Ghana; Humans; Infant; Infant, Newborn; Lumefantrine; Malaria; Male; Pyrimethamine; Quinolines; Rain; Seasons; Sulfadoxine | 2016 |
A Phase 3, Double-Blind, Randomized Study of Arterolane Maleate-Piperaquine Phosphate vs Artemether-Lumefantrine for Falciparum Malaria in Adolescent and Adult Patients in Asia and Africa.
Topics: Adolescent; Adult; Africa; Aged; Antimalarials; Artemether; Artemisinins; Asia; Child; Double-Blind Method; Drug Therapy, Combination; Ethanolamines; Female; Fluorenes; Half-Life; Heterocyclic Compounds, 1-Ring; Humans; India; Lumefantrine; Malaria, Falciparum; Male; Middle Aged; Peroxides; Plasmodium falciparum; Quinolines; Spiro Compounds; Young Adult | 2016 |
Artemether-Lumefantrine versus Dihydroartemisinin-Piperaquine for Treatment of Uncomplicated Plasmodium falciparum Malaria in Children Aged Less than 15 Years in Guinea-Bissau - An Open-Label Non-Inferiority Randomised Clinical Trial.
Topics: Antimalarials; Artemether; Artemisinins; Child; Ethanolamines; Fluorenes; Guinea-Bissau; Humans; Lumefantrine; Malaria, Falciparum; Quinolines; Treatment Outcome | 2016 |
Pharmacokinetic Interactions between Tafenoquine and Dihydroartemisinin-Piperaquine or Artemether-Lumefantrine in Healthy Adult Subjects.
Topics: Adolescent; Adult; Aged; Aminoquinolines; Antimalarials; Artemisinins; Drug Interactions; Drug Therapy, Combination; Ethanolamines; Female; Fluorenes; Half-Life; Healthy Volunteers; Humans; Lumefantrine; Malaria, Vivax; Male; Middle Aged; Plasmodium vivax; Quinolines; Young Adult | 2016 |
Changing Antimalarial Drug Sensitivities in Uganda.
Topics: Adolescent; Amodiaquine; Antimalarials; Artemisinins; Aspartic Acid Endopeptidases; Child; Child, Preschool; Chloroquine; Drug Resistance; Ethanolamines; Female; Fluorenes; Gene Expression; Humans; Infant; Inhibitory Concentration 50; Lumefantrine; Malaria, Falciparum; Male; Mefloquine; Membrane Transport Proteins; Multidrug Resistance-Associated Proteins; Mutation; Parasitic Sensitivity Tests; Plasmodium falciparum; Protozoan Proteins; Quinolines; Uganda; Young Adult | 2017 |
Efficacy of artesunate-amodiaquine, dihydroartemisinin-piperaquine and artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Maradi, Niger.
Topics: Amodiaquine; Antimalarials; Artemisinins; Child, Preschool; Drug Combinations; Female; Humans; Infant; Kaplan-Meier Estimate; Lumefantrine; Malaria, Falciparum; Male; Niger; Parasite Load; Quinolines | 2018 |
31 other study(ies) available for piperaquine and lumefantrine
| Article | Year |
|---|---|
Determinants of in vitro drug susceptibility testing of Plasmodium vivax.
Topics: Animals; Antimalarials; Chloroquine; Humans; Inhibitory Concentration 50; Life Cycle Stages; Parasitic Sensitivity Tests; Plasmodium falciparum; Plasmodium vivax; Schizonts; Time Factors | 2008 |
In vivo and in vitro efficacy of amodiaquine monotherapy for treatment of infection by chloroquine-resistant Plasmodium vivax.
Topics: Adolescent; Age Distribution; Amodiaquine; Animals; Antimalarials; Chloroquine; Confidence Intervals; Drug Resistance; Drug Tolerance; Female; Follow-Up Studies; Humans; Inhibitory Concentration 50; Male; Outpatients; Parasitemia; Plasmodium vivax; Prospective Studies; Recurrence; Rural Health; Time Factors; Treatment Failure; Treatment Outcome | 2009 |
In vitro chemosensitization of Plasmodium falciparum to antimalarials by verapamil and probenecid.
Topics: Adjuvants, Pharmaceutic; Animals; Antimalarials; Parasitic Sensitivity Tests; Plasmodium falciparum; Probenecid; Verapamil | 2009 |
In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1.
Topics: Animals; Antimalarials; Artemisinins; Ethanolamines; Fluorenes; Genotype; Humans; Lumefantrine; Malaria, Falciparum; Membrane Transport Proteins; Microbial Sensitivity Tests; Multidrug Resistance-Associated Proteins; Plasmodium falciparum; Polymorphism, Genetic; Protozoan Proteins; Quinolines | 2009 |
In vitro activities of quinine and other antimalarials and pfnhe polymorphisms in Plasmodium isolates from Kenya.
Topics: Amino Acid Sequence; Animals; Antimalarials; Drug Resistance; Humans; Kenya; Mefloquine; Membrane Transport Proteins; Molecular Sequence Data; Multidrug Resistance-Associated Proteins; Parasitic Sensitivity Tests; Phenanthrenes; Plasmodium falciparum; Polymorphism, Genetic; Protozoan Proteins; Quinine; Sequence Analysis, DNA; Sodium-Hydrogen Exchangers | 2010 |
Discovery and Structural Optimization of Acridones as Broad-Spectrum Antimalarials.
Topics: Acridones; Animals; Antimalarials; Disease Models, Animal; Drug Discovery; Hep G2 Cells; Humans; Malaria; Mice; Plasmodium; Species Specificity; Structure-Activity Relationship | 2019 |
Lead Optimization of Second-Generation Acridones as Broad-Spectrum Antimalarials.
Topics: Acridones; Administration, Oral; Animals; Antimalarials; Cell Survival; Disease Models, Animal; Female; Half-Life; Hep G2 Cells; Humans; Life Cycle Stages; Malaria; Male; Mice; Mice, Inbred C57BL; Plasmodium falciparum; Structure-Activity Relationship | 2020 |
Antimalarial therapies in children from Papua New Guinea.
Topics: Antimalarials; Artemether; Artemisinins; Biological Availability; Drug Therapy, Combination; Ethanolamines; Fats; Fluorenes; Humans; Lumefantrine; Malaria; Quinolines; Treatment Failure | 2009 |
Plasmodium berghei ANKA: selection of resistance to piperaquine and lumefantrine in a mouse model.
Topics: Amodiaquine; Animals; Antimalarials; Artemisinins; Chloroquine; Disease Models, Animal; Drug Resistance; Ethanolamines; Female; Fluorenes; Lumefantrine; Malaria; Male; Mice; Parasitemia; Plasmodium berghei; Quinolines; Serial Passage | 2009 |
Selection of known Plasmodium falciparum resistance-mediating polymorphisms by artemether-lumefantrine and amodiaquine-sulfadoxine-pyrimethamine but not dihydroartemisinin-piperaquine in Burkina Faso.
Topics: Amodiaquine; Antimalarials; Artemether; Artemisinins; Burkina Faso; Drug Combinations; Drug Resistance, Bacterial; Ethanolamines; Fluorenes; Genotype; Humans; Infant; Lumefantrine; Malaria, Falciparum; Membrane Transport Proteins; Multidrug Resistance-Associated Proteins; Plasmodium falciparum; Polymorphism, Single Nucleotide; Protozoan Proteins; Pyrimethamine; Quinolines; Randomized Controlled Trials as Topic; Recurrence; Sulfadoxine | 2010 |
Quantitative assessment of Plasmodium falciparum sexual development reveals potent transmission-blocking activity by methylene blue.
Topics: Amodiaquine; Animals; Anopheles; Antimalarials; Artemisinins; Blotting, Southern; Dose-Response Relationship, Drug; Ethanolamines; Fluorenes; Genetic Vectors; Germ Cells, Plant; Green Fluorescent Proteins; Luciferases; Lumefantrine; Malaria; Methylene Blue; Naphthyridines; Plasmodium falciparum; Quinolines; Sexual Development | 2011 |
Ex vivo responses of Plasmodium falciparum clinical isolates to conventional and new antimalarial drugs in Niger.
Topics: Amodiaquine; Antimalarials; Artemisinins; Chloroquine; Drug Resistance; Ethanolamines; Fluorenes; Humans; Lumefantrine; Malaria, Falciparum; Naphthyridines; Niger; Parasitic Sensitivity Tests; Plasmodium falciparum; Quinolines | 2013 |
In vitro interaction of lumefantrine and piperaquine by atorvastatin against Plasmodium falciparum.
Topics: Antimalarials; Atorvastatin; Drug Synergism; Ethanolamines; Fluorenes; Heptanoic Acids; Inhibitory Concentration 50; Lumefantrine; Parasitic Sensitivity Tests; Plasmodium falciparum; Pyrroles; Quinolines | 2014 |
Contrasting benefits of different artemisinin combination therapies as first-line malaria treatments using model-based cost-effectiveness analysis.
Topics: Africa; Antimalarials; Artemisinins; Cost-Benefit Analysis; Ethanolamines; Fluorenes; Humans; Lumefantrine; Malaria, Falciparum; Models, Theoretical; Quinolines; Seasons | 2014 |
Piperaquine and Lumefantrine resistance in Plasmodium berghei ANKA associated with increased expression of Ca2+/H+ antiporter and glutathione associated enzymes.
Topics: Animals; Antimalarials; Antiporters; Cation Transport Proteins; Cloning, Molecular; DNA, Protozoan; Drug Resistance, Multiple; Ethanolamines; Fluorenes; Gene Expression Regulation, Enzymologic; Glutathione; Glutathione Peroxidase; Glutathione Reductase; Glutathione Transferase; Lumefantrine; Male; Mice; Parasitic Sensitivity Tests; Plasmodium berghei; Quinolines; Real-Time Polymerase Chain Reaction; Sequence Analysis, DNA | 2014 |
Fitness cost of resistance for lumefantrine and piperaquine-resistant Plasmodium berghei in a mouse model.
Topics: Animals; Antimalarials; Disease Models, Animal; Drug Resistance; Ethanolamines; Fluorenes; Genetic Fitness; Lumefantrine; Malaria; Male; Mice; Plasmodium berghei; Quinolines | 2015 |
Impact of antimalarial treatment and chemoprevention on the drug sensitivity of malaria parasites isolated from ugandan children.
Topics: Amodiaquine; Antimalarials; Artemisinins; Child, Preschool; Chloroquine; Clinical Trials as Topic; Ethanolamines; Fluorenes; Humans; Infant; Lumefantrine; Membrane Transport Proteins; Multidrug Resistance-Associated Proteins; Parasitic Sensitivity Tests; Plasmodium falciparum; Polymorphism, Genetic; Protozoan Proteins; Quinine; Quinolines; Uganda | 2015 |
In Vitro Activities of Primaquine-Schizonticide Combinations on Asexual Blood Stages and Gametocytes of Plasmodium falciparum.
Topics: Antimalarials; Benzothiazoles; Chloroquine; Diamines; Drug Combinations; Drug Interactions; Erythrocytes; Ethanolamines; Flow Cytometry; Fluorenes; Humans; Lumefantrine; Mefloquine; Organic Chemicals; Parasitic Sensitivity Tests; Plasmodium falciparum; Primaquine; Quinolines; Sporozoites; Trophozoites | 2015 |
Assessment of pharmacokinetic compatibility of short acting CDRI candidate trioxane derivative, 99-411, with long acting prescription antimalarials, lumefantrine and piperaquine.
Topics: Animals; Antimalarials; Chromatography, High Pressure Liquid; Ethanolamines; Fluorenes; Half-Life; Heterocyclic Compounds; Humans; Lumefantrine; Microsomes, Liver; Phenanthrenes; Quinolines; Rats; Spiro Compounds; Tandem Mass Spectrometry | 2015 |
Absence of Association between Polymorphisms in the RING E3 Ubiquitin Protein Ligase Gene and Ex Vivo Susceptibility to Conventional Antimalarial Drugs in Plasmodium falciparum Isolates from Dakar, Senegal.
Topics: Antimalarials; Artemisinins; Artesunate; Chloroquine; Doxycycline; Ethanolamines; Fluorenes; Lumefantrine; Mefloquine; Naphthyridines; Plasmodium falciparum; Polymorphism, Genetic; Quinine; Quinolines; Senegal; Ubiquitin-Protein Ligases | 2016 |
Hemolysis after Oral Artemisinin Combination Therapy for Uncomplicated Plasmodium falciparum Malaria.
Topics: Administration, Oral; Adolescent; Adult; Anemia; Antimalarials; Artemether; Artemisinins; Child; Drug Therapy, Combination; Ethanolamines; Female; Fluorenes; Hemolysis; Humans; Lumefantrine; Malaria, Falciparum; Male; Prospective Studies; Quinolines | 2016 |
Association between Polymorphisms in the Pf
Topics: Amodiaquine; Antimalarials; Artemisinins; Artesunate; Asparagine; ATP-Binding Cassette Transporters; Chloroquine; Doxycycline; Drug Resistance; Ethanolamines; Fluorenes; Gene Expression; Humans; Inhibitory Concentration 50; Lumefantrine; Malaria, Falciparum; Mefloquine; Naphthyridines; Plasmodium falciparum; Polymorphism, Genetic; Protein Isoforms; Protozoan Proteins; Quinine; Quinolines; Repetitive Sequences, Amino Acid; Senegal | 2017 |
[Elimination in South-East Asia? The role of antimalarial drugs].
Topics: Antimalarials; Artemether; Artemisinins; Asia, Southeastern; Disease Eradication; Drug Therapy, Combination; Ethanolamines; Fluorenes; Humans; Lumefantrine; Malaria, Falciparum; Quinolines | 2016 |
Factors contributing to anaemia after uncomplicated falciparum malaria in under five year-old Nigerian children ten years following adoption of artemisinin-based combination therapies as first-line antimalarials.
Topics: Amodiaquine; Anemia; Antimalarials; Area Under Curve; Artemisinins; Child, Preschool; Drug Combinations; Drug Therapy, Combination; Ethanolamines; Female; Fluorenes; Follow-Up Studies; Hematocrit; Humans; Infant; Kaplan-Meier Estimate; Logistic Models; Lumefantrine; Malaria, Falciparum; Male; Nigeria; Odds Ratio; Quinolines; ROC Curve; Treatment Outcome | 2017 |
Topics: Anti-Bacterial Agents; Antimalarials; Artemether; Artemisinins; Atovaquone; Azithromycin; Chloroquine; Doxycycline; Ethanolamines; Fluorenes; Humans; India; Lumefantrine; Malaria, Falciparum; Mefloquine; Plasmodium falciparum; Quinine; Quinolines | 2017 |
Changing Molecular Markers of Antimalarial Drug Sensitivity across Uganda.
Topics: Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Aspartic Acid Endopeptidases; Child; Chloroquine; Drug Resistance; Folic Acid Antagonists; Humans; Lumefantrine; Malaria, Falciparum; Membrane Transport Proteins; Multidrug Resistance-Associated Proteins; Plasmodium falciparum; Polymorphism, Single Nucleotide; Protozoan Proteins; Quinolines; Uganda | 2019 |
Improving Methods for Analyzing Antimalarial Drug Efficacy Trials: Molecular Correction Based on Length-Polymorphic Markers
Topics: Algorithms; Antigens, Protozoan; Antimalarials; Artemisinins; Biomarkers; Clinical Trials as Topic; Gene Expression; Humans; Lumefantrine; Malaria, Falciparum; Mefloquine; Merozoite Surface Protein 1; Models, Statistical; Parasitic Sensitivity Tests; Plasmodium falciparum; Polymorphism, Restriction Fragment Length; Protozoan Proteins; Quinolines; Time Factors; Treatment Outcome | 2019 |
Ex-vivo Sensitivity of Plasmodium falciparum to Common Anti-malarial Drugs: The Case of Kéniéroba, a Malaria Endemic Village in Mali.
Topics: Adolescent; Amodiaquine; Antimalarials; Artemisinins; Child; Child, Preschool; Chloroquine; Drug Resistance; Endemic Diseases; Humans; Infant; Inhibitory Concentration 50; Lumefantrine; Malaria, Falciparum; Mali; Mefloquine; Plasmodium falciparum; Quinine; Quinolines | 2020 |
Plasmodium falciparum genetic factors rather than host factors are likely to drive resistance to ACT in Ghana.
Topics: Amodiaquine; Antimalarials; Child; Child, Preschool; Drug Resistance; Ghana; Humans; Infant; Infant, Newborn; Lumefantrine; Multidrug Resistance-Associated Proteins; Plasmodium falciparum; Polymorphism, Genetic; Quinolines | 2020 |
Balanced impacts of fitness and drug pressure on the evolution of PfMDR1 polymorphisms in Plasmodium falciparum.
Topics: Antimalarials; Chloroquine; Genetic Fitness; Haplotypes; Lumefantrine; Multidrug Resistance-Associated Proteins; Mutation; Plasmodium falciparum; Quinolines | 2021 |
Prevalence of mutations in the cysteine desulfurase IscS (Pfnfs1) gene in recurrent Plasmodium falciparum infections following artemether-lumefantrine (AL) and dihydroartemisinin-piperaquine (DP) treatment in Matayos, Western Kenya.
Topics: Antimalarials; Artemether; Artemether, Lumefantrine Drug Combination; Drug Combinations; Humans; Kenya; Lumefantrine; Malaria; Malaria, Falciparum; Mutation; Plasmodium falciparum; Prevalence; Quinolines; Reinfection | 2023 |